California State Teachers Retirement System Lowers Stake in Emergent Biosolutions, Inc. (EBS)

California State Teachers Retirement System cut its holdings in Emergent Biosolutions, Inc. (NYSE:EBS) by 7.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,374 shares of the biopharmaceutical company’s stock after selling 4,637 shares during the quarter. California State Teachers Retirement System owned approximately 0.14% of Emergent Biosolutions worth $2,013,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Riverhead Capital Management LLC grew its position in shares of Emergent Biosolutions by 102.8% in the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,542 shares during the last quarter. Creative Planning boosted its position in Emergent Biosolutions by 1.2% during the second quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 55 shares during the last quarter. Laurion Capital Management LP acquired a new stake in Emergent Biosolutions during the second quarter worth approximately $214,000. State of Alaska Department of Revenue boosted its position in Emergent Biosolutions by 79.9% during the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the biopharmaceutical company’s stock worth $232,000 after acquiring an additional 3,051 shares during the last quarter. Finally, OppenheimerFunds Inc. boosted its position in Emergent Biosolutions by 23.0% during the first quarter. OppenheimerFunds Inc. now owns 12,558 shares of the biopharmaceutical company’s stock worth $364,000 after acquiring an additional 2,351 shares during the last quarter. Institutional investors and hedge funds own 85.97% of the company’s stock.

Shares of Emergent Biosolutions, Inc. (EBS) opened at $40.44 on Wednesday. Emergent Biosolutions, Inc. has a 1 year low of $25.96 and a 1 year high of $44.86. The stock has a market cap of $1,691.83, a P/E ratio of 21.62, a P/E/G ratio of 1.13 and a beta of 1.22. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.32. The company had revenue of $149.43 million for the quarter, compared to the consensus estimate of $124.55 million. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. Emergent Biosolutions’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.56 earnings per share. analysts forecast that Emergent Biosolutions, Inc. will post 1.64 EPS for the current year.

EBS has been the topic of a number of analyst reports. BidaskClub lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Zacks Investment Research lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $45.00.

In other Emergent Biosolutions news, Director George A. Joulwan sold 14,251 shares of the stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $41.24, for a total transaction of $587,711.24. Following the transaction, the director now owns 34,323 shares of the company’s stock, valued at $1,415,480.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Adam Havey sold 7,885 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $37.06, for a total transaction of $292,218.10. Following the transaction, the executive vice president now directly owns 33,931 shares in the company, valued at approximately $1,257,482.86. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 215,210 shares of company stock worth $8,543,174. 16.50% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “California State Teachers Retirement System Lowers Stake in Emergent Biosolutions, Inc. (EBS)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/11/15/california-state-teachers-retirement-system-lowers-stake-in-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply